Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics, Inc. said they are revising their 2017 partnership to address severe pediatric epilepsies on 3 March, with a new agreement that gives the Japanese pharma full development and commercial rights to Phase III-ready soticlestat, while Ovid avoids significant R&D spending commitments and monetizes its share of the drug candidate. Takeda plans to launch Phase III trials of soticlestat in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) during the second quarter of 2021.
[Sidebar#SC098066]








